HDAC9 and cancer: Combination therapy with SAHA and PLD2 inhibitor significantly suppressed cell proliferation and angiogenesis and enhanced apoptosis of breast cancer cells, suggesting that combined treatment with these drugs might offer a promising therapeutic approach to the treatment of cancer by overcoming resistance to HDAC inhibitors.